Dynamic Healthcare M&A Database

Acquiring Party	Ortho-McNeil Pharmaceuticals, Inc. (a Johnson & Johnson subsidiary), a global manufacturer pharmaceuticals, services and healthcare information.
Transferring Party	Peninsula Pharmaceuticals, Inc., privately-held biopharmaceutical company focused on developing antibiotics to treat life-threatening infections.
Sector	Biopharmaceuticals
Date	July 11, 2005
Analysis Through the acquisition J&J will own Peninsula’s lead product, doripenem, a broad-spectrum antibiotic. Deal value about $245 million. Doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 3Q05